CORT
NASDAQ
US
Corcept Therapeutics Incorporated - Common Stock
$42.49
▲ +$0.51
(+1.21%)
Vol 1.5M
11
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$3.7B
P/E
34.5
ROE
16.1%
Margin
14.3%
D/E
0.00
Beta
0.18
52W
$49–$117
Wall Street Consensus
12 analysts · Apr 20262
Strong Buy
7
Buy
3
Hold
0
Sell
0
Strong Sell
75.0%
Buy Rating
Price Chart
Similar Stocks
AXSM
Axsome Therapeutics Inc
$9.2B
BLTE
Belite Bio Inc
$5.6B
TERN
Terns Pharmaceuticals Inc
$4.3B
LGND
Ligand Pharmaceuticals Inc
P/E 76.6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35.8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.31 | $0.20 | $-0.11 |
| Sep 2025 | $0.14 | $0.16 | +$0.02 |
| Jun 2025 | $0.19 | $0.29 | +$0.10 |
| Mar 2025 | $0.15 | $0.17 | +$0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $181.9M | $157.2M | $194.4M | $207.6M | $202.1M |
| Net Income | — | $30.7M | $20.5M | $35.1M | $19.7M | $24.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 20.3% | 20.3% | 20.3% | 20.3% | 16.1% | 16.1% |
| P/E (TTM) | 58.24 | 55.72 | 67.13 | 57.92 | 78.80 | 34.50 |
| Net Margin | 18.1% | 18.7% | 18.7% | 18.7% | 14.3% | 14.3% |
| Gross Margin | 98.2% | 98.4% | 98.4% | 98.4% | 98.2% | 98.2% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.06 | 3.06 | 3.06 | 3.06 | 3.14 | 3.14 |
Key Ratios
ROA (TTM)
12.8%
P/S (TTM)
4.94
P/B
7.8
EPS (TTM)
$0.89
CF/Share
$0.81
Rev Growth 3Y
+22.6%
52W High
$117.33
52W Low
$49.00
$49.00
52-Week Range
$117.33
Financial Health
Free Cash Flow
$38.4M
Net Debt
-$114.4M
Cash
$120.5M
Total Debt
$6.1M
As of Dec 31, 2025
How does CORT compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
CORT valuation vs Pharmaceuticals peers
P/E ratio
34.5
▲
13%
above
peers
(30.7)
vs Peers
vs Industry
Undervalued
P/S ratio
4.9
▼
27%
below
peers
(6.7)
vs Peers
vs Industry
Pricier
P/B ratio
7.8
▲
49%
above
peers
(5.2)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
CORT profitability vs Pharmaceuticals peers
ROE
16.1%
▲
162%
above
peers
(-26.1%)
vs Peers
vs Industry
Top tier
Net margin
14.3%
▲
1088%
above
peers
(-1.5%)
vs Peers
vs Industry
Below avg
Gross margin
98.2%
▲
10%
above
peers
(88.9%)
vs Peers
vs Industry
In line
ROA
12.8%
▲
236%
above
peers
(-9.5%)
vs Peers
vs Industry
Top tier
CORT financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(27.4)
vs Peers
vs Industry
Low debt
Current ratio
3.1
▼
10%
below
peers
(3.5)
vs Peers
vs Industry
In line
Beta
0.2
▼
70%
below
peers
(0.6)
vs Peers
vs Industry
More volatile
CORT fundamentals radar
CORT
Peer median
Industry
CORT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CORT vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
BELANOFF JOSEPH K
Chief Executive Officer · Mar 25
26198 shs
GUYER WILLIAM
Officer · Mar 20
11767 shs
GUYER WILLIAM
Officer · Mar 20
11767 shs
WILSON JAMES N
Director · Mar 20
4000 shs
BAKER GEORGE LEONARD JR.
Director · Mar 17
100000 shs
MAHONEY DAVID L
Director · Mar 13
30000 shs
WILSON JAMES N
Director · Mar 13
28000 shs
MAHONEY DAVID L
Director · Mar 13
24531 shs
GUYER WILLIAM
Officer · Mar 04
8233 shs
GUYER WILLIAM
Officer · Mar 04
8233 shs
Last 90 days
Top Holders
Top 5: 36.09%Blackrock Inc.
11.34%
$453.5M
Vanguard Group Inc
8.93%
$357.0M
Ingalls & Snyder LLC
6.76%
$270.5M
Renaissance Technologies, L…
5.41%
$216.5M
Parallel Advisors, LLC
3.65%
$145.9M
As of Dec 31, 2025